VIDEO: ARMOR study shows MRSA resistance still significant

DENVER — The incidence of methicillin-resistant Staphylococcus aureus has gone down slightly but is still significant at 37%, Penny A. Asbell, MD, MBA, FARVO, said at the ARVO meeting. The ARMOR surveillance study also showed that resistance to vancomycin and besifloxacin remains low, so they may be good choices for immediate treatment, she said.

DENVER — The incidence of methicillin-resistant Staphylococcus aureus has gone down slightly but is still significant at 37%, Penny A. Asbell, MD, MBA, FARVO, said at the ARVO meeting. The ARMOR surveillance study also showed that resistance to vancomycin and besifloxacin remains low, so they may be good choices for immediate treatment, she said.